Clinically, the GRP78 inhibitor HA15 specifically inhibits the activity of GRP78 in malignant pleural mesothelioma and melanoma by binding to its ATPase domain [15, 47], which is the domain responsible for the interaction of GRP78 with LINC00662. Here, DNAH8 is linked to malignant pleural mesothelioma.